1. Home
  2. NRT vs IMA Comparison

NRT vs IMA Comparison

Compare NRT & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NRT

North European Oil Royality Trust

SELL

Current Price

$6.51

Market Cap

81.0M

Sector

Energy

ML Signal

SELL

IMA

ImageneBio Inc.

SELL

Current Price

$3.89

Market Cap

66.3M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NRT
IMA
Founded
1975
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.0M
66.3M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
NRT
IMA
Price
$6.51
$3.89
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $18.00
AVG Volume (30 Days)
★ 49.2K
14.3K
Earning Date
12-30-2026
11-09-2026
Dividend Yield
★ 12.48%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.70
N/A
Revenue
N/A
★ $800,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.31
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$5.63
$3.00
52 Week High
$10.49
$7.60

Technical Indicators

Market Signals
Indicator
NRT
IMA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NRT
IMA

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Share on Social Networks: